Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5736-5746

  Fernandez, Regina ^a   Paz, Liliana I ^a   Rosato, Roberto R ^a   Rosato, Adriana E ^b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CEFOXITIN; CEFTAROLINE; IMIPENEM; NAFCILLIN; OXACILLIN; ANTIINFECTIVE AGENT; BETA LACTAM; CEPHALOSPORIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DNA REPAIR; DRUG SUBSTITUTION; DRUG WITHDRAWAL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTAGENESIS; MUTATION RATE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CEPHALOSPORINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84907279803     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03019-14     Document Type: Article

References (32)

1. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-598. http://dx.doi.org/10.1001/jama.279.8.593.
2. Pinho MG, LHde Tomasz A. 1998. Transcriptional analysis of the Staphylococcus aureus penicillin binding protein 2 gene. J. Bacteriol. 180:6077-6081.
3. Pinho MG, Filipe SR, de Lencastre H, Tomasz A. 2001. Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus. J. Bacteriol. 183:6525-6531. http://dx.doi.org/10.1128/JB.183.22.6525-6531.2001.
4. Pinho MG, Errington J. 2005. Recruitment of penicillin-binding protein PBP2 to the division site of Staphylococcus aureus is dependent on its transpeptidation substrates. Mol. Microbiol. 55:799-807. http://dx.doi.org/10.1111/j.1365-2958.2004.04420.X.
5. Finan JE, Rosato AE, Dickinson TM, Ko D, Archer GL. 2002. Conversion of oxacillin-resistant staphylococci from heterotypic to homotypic resistance expression. Antimicrob. Agents Chemother. 46:24-30. http://dx.doi.org/10.1128/AAC.46.1.24-30.2002.
6. Rohrer S, Maki H, Berger-Bachi B. 2003. What makes resistance to methicillin heterogeneous? J. Med. Microbiol. 52:605-607. http://dx.doi.org/10.1099/jmm.0.05176-0.
7. File TM, Jr., Wilcox MH, Stein GE. 2012. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin. Infect. Dis. 55(Suppl. 3): S173-S180. http://dx.doi.org/10.1093/cid/cis559.
8. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob. Agents Chemother. 56:2933-2940. http: //dx.doi.org/10.1128/AAC.00330-12.
9. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-Lopez C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA. 2013. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc. Natl. Acad. Sci. U. S. A. 110:16808-16813. http://dx.doi.org/10.1073/pnas.1300118110.
10. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. 2008. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J. Am. Chem. Soc. 130:9212-9213. http://dx.doi.org/10.1021/ja8029448.
11. Sader HS, Flamm RK, Jones RN. 2013. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob. Agents Chemother. 57:3178-3181. http://dx.doi.org/10.1128/AAC.00484-13.
12. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-nonsusceptibie Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030. http://dx.doi.org/10.1128/AAC.01516-09.
13. Cuirolo A, Plata K, Rosato AE. 2009. Development of homogeneous expression of resistance in methicillin-resistant Staphylococcus aureus clinical strains is functionally associated with a beta-lactam-mediated SOS response. J. Antimicrob. Chemother. 64:37-45. http://dx.doi.org/10.1093/jac/dkp164.
14. Plata KB, Rosato RR, Rosato AE. 2011. Fate of mutation rate depends on agr locus expression during oxacillin-mediated heterogeneous-homogeneous selection in methicillin-resistant Staphylococcus aureus clinical strains. Antimicrob. Agents Chemother. 55:3176-3186. http://dx. doi.org/10.1128/AAC.01119-09.
15. National Committee for Clinical Laboratory Standards. 2007. Performance standards for antimicrobial disk susceptibility tests, 8th ed. approved standard M2-A8. National Commitee for Clinical Laboratory Standards, Wayne, PA.
16. Forbes BA, Bombicino K, Plata K, Cuirolo A, Webber D, Bender CL, Rosato AE. 2008. Unusual form of oxacillin resistance in methicillinresistant Staphylococcus aureus clinical strains. Diagn. Microbiol. Infect. Dis. 61:387-395. http://dx.doi.org/10.1016/j.diaginicrobio.2008.04.003.
17. Plata KB, Riosa S, Singh CR, Rosato RR, Rosato AE. 2013. Targeting of PBP1 by beta-lactams determines recA/SOS response activation in heterogeneous MRSA clinical strains. PLoS One 8:e61083. http://dx.doi.org/10.1371/journal.pone.0061083.
18. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408. http://dx.doi.org/10.1006/meth.2001.1262.
19. Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, Bell J, Coombs G, Bennett-Wood V, Porter JL, Robins-Browne R, Davies JK, Seemann T, Stinear TP. 2011. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two-component regulator WalKR. PLoS Pathog. 7:e1002359. http://dx.doi.org/10.1371/journal.ppat.1002359.
20. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. ß-Lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAP-resistant derivatives. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.01525-12.
21. Desbois AP, Coote PJ. 2011. Wax moth larva (Galleria mellonella): an in vivo model for assessing the efficacy of antistaphylococcal agents. J. Antimicrob. Chemother. 66:1785-1790. http://dx.doi.org/10.1093/jac/dkr198.
22. Kavanagh K, Reeves EP. 2004. Exploiting the potential of insects for in vivo pathogenicity testing of microbial pathogens. FEMS Microbiol. Rev. 28:101-112. http://dx.doi.org/10.1016/j.femsre.2003.09.002.
23. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Jr., My-lonakis E. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob. Agents Chemother. 53:2605-2609. http://dx.doi.org/10.1128/AAC.01533-08.
24. Olsen RJ, Watkins ME, Cantu CC, Beres SB, Musser JM. 2011. Virulence of serotype M3 group A Streptococcus strains in wax worms (Galleria mellonella larvae). Virulence 2:111-119. http://dx.doi.org/10.4161/viru.2.2.14338.
25. Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP, Lahiri SD. 28 April 2014. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J. Antimicrob. Chemother.
26. Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowska-Shick K. 2012. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J. Antimicrob. Chemother. 67:1321-1324. http://dx.doi.org/10.1093/jac/dks069.
27. Napolitano R, Janel-Bintz R, Wagner J, Fuchs RP. 2000. All three SOS-inducible DNA polymerases (Pol II, Pol IV, and Pol V) are involved in induced mutagenesis. EMBO J. 19:6259-6265. http://dx.doi.org/10.1093/emboj/19.22.6259.
28. Fish DN, Piscitelli SC, Danziger LH. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.
29. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, Biek D, Critchley IA, Diekema DJ, Doern GV. 2011. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob. Agents Chemother. 55:4154-4160. http://dx.doi.org/10.1128/AAC.00315-11.
30. Tan CM, Therien AG, Lu J, Lee SH, Caron A, Gill CJ, Lebeau-Jacob C, Benton-Perdomo L, Monteiro JM, Pereira PM, Elsen NL, Wu J, Deschamps K, Petcu M, Wong S, Daigneault E, Kramer S, Liang L, Maxwell E, Claveau D, Vaillancourt J, Skorey K, Tam J, Wang H, Meredith TC, Sillaots S, Wang-Jarantow L, Ramtohul Y, Langlois E, Landry F, Reid JC, Parthasarathy G, Sharma S, Baryshnikova A, Lumb KJ, Pinho MG, Soisson SM, Roemer T. 2012. Restoring methicillin-resistant Staphylococcus aureus susceptibility to ß-lactam antibiotics. Sci. Transl. Med. 4:126ra35. http://dx.doi.org/10.1126/scitranslmed.3003592.
31. Jones RN, Flamm RK, Sader HS, Stilwell MG. 2013. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically indicated species. Diagn. Microbiol. Infect. Dis. 75:89-93. http://dx.doi.org/10.1016/j.diagmicrobio.2012.08.022.
32. Boyle-Vavra S, Yin S, Challapalli M, Daum RS. 2003. Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin. Antimicrob. Agents Chemother. 47:1028-1036. http://dx.doi.org/10.1128/AAC.47.3.1028-1036.2003.